Please select the option that best describes you:
Topics:
Hematologic Malignancies • Medical Oncology • Myeloma • Internal Medicine • Hematology • Journal Club ft. NEJM publications • Multiple Myeloma
What clinical or logistical factors influence your choice of anti-CD38 antibody in first line treatment of Multiple Myeloma?
For example, per the IMROZ trial methodology, Isatuximab dosing does not change to monthly dosing until >18 cycles which can impact patient QoL and infusion times. In a real-world setting, would this or other factors influence your treatment decisions?
Answer from: Medical Oncologist at Academic Institution
Off-trial, we tend to offer anti-CD38 to all newly diagnosed patients due to the ease of administration, particularly in renal failure. Most of the time we use daratumumab, unless patients are receiving another in-clinic medication, e.g. carfilzomib. I assume isatuximab will proceed with the develop...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
I generally use daratumumab, because subcutaneous is more convenient for patients, and we go to once-a-month dosing much quicker with daratumumab compared to isatuximab. Once isatuximab subcutaneous is available, this advantage of daratumumab may be lost, but given comfort and familiarity with darat...
Answer from: Medical Oncologist at Academic Institution
I agree with Dr. @Mohyuddin, Dara has been used longer and is easier to administer due to the subq formulation. Isatuximab is somewhat different than Dara and is an IV infusion. However, I have used both in 1st line and find both to be very effective when used in front-line quad induction.
In...